BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

27 Jun 2024 06:40:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

17 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

13 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

04 Jun 2024 07:50:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

24 May 2024 18:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Provides First Quarter 2024 Business Update

14 May 2024 15:10:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

08 May 2024 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

30 Apr 2024 15:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

30 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

16 Apr 2024 06:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

08 Apr 2024 06:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

03 Apr 2024 15:38:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

01 Apr 2024 06:45:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

11 Mar 2024 15:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

06 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

05 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

01 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

12 Dec 2023 08:15:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

09 Oct 2023 11:10:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

12 Sep 2023 08:00:00 By Nasdaq GlobeNewswire